News

Zacks Investment Research on MSN1h
Regeneron Initial Data on Multiple Myeloma Drug Encouraging
Regeneron Pharmaceuticals, Inc. REGN announced encouraging initial results from two cohorts of the early-stage study on ...
The Hudson Independent1d
Regeneron Enters into Agreement to Acquire Consumer Genetics Business
Tarrytown-based Regeneron Pharmaceuticals, Inc. has announced it has been named the successful bidder in the bankruptcy ...
Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data
Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...
Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions
It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly ...
Bayer wins EU recommendation for label expansion of Regeneron-partnered Eylea
Bayer A.G. (OTCPK:BAYZF) (OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the label ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Made A “Very Smart Deal,” Says Jim Cramer
We recently published a list of Jim Cramer Reveals “Quiet” Stock That Goes Up In This List Of 12 Stocks. In this article, we ...
Explore more
The Manila Times1d
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition
Not unlike Regeneron's acquisition of 23andMe, Predictive Oncology's AI-driven breakthroughs reflect a broader transformation ...
Regeneron's 23andMe Steal - Smart Genetics Play That Won't Cure Near-Term Growth Pains
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.